01—Abstract
Summary
Summary of the 8-K filed May 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences (EW) filed an 8-K on May 4, 2026 announcing that Theodora ("Doretta") Mistras will become Corporate Vice President and Chief Financial Officer, effective May 29, 2026, succeeding Scott Ullem, who had announced his planned transition in October 2025 and will remain on as a strategic advisor.
Mistras comes from Viatris, where she has been CFO since March 2024, and previously spent time as a managing director in healthcare investment banking at Citigroup and Goldman Sachs. The appointment is a planned, orderly leadership transition rather than a response to a performance issue, and the filing discloses no changes to guidance or financial results. The compensation package is substantial and signals the company's intent to secure a seasoned finance leader.
It includes a base salary of $925,000,a a target annual bonus of at least 100% of base salary, a $2,013,000 sign-on bonus subject to a 24-month clawback for voluntary resignation or termination for misconduct, and an initial RSU grant with a $8,000,000 grant-date value vesting 43.75%, 50%, and 6.25% over three years. She is also slated for a fiscal 2026 annual equity award with a $4,500,000 grant-date value. Full vesting of the initial RSUs is triggered by termination without Cause, resignation for Good Reason, or death or disability, which are standard protections for executive retention.
For investors, the key takeaways are continuity in financial leadership through a planned handover, a new CFO with a deep capital markets and healthcare investment banking background, and a compensation structure that aligns her incentives with multi-year stock performance. The filing does not disclose any financial metrics, guidance, or reasons beyond the stated transition, so the market impact is likely to be limited absent further commentary from management.
02—Key points
Key Highlights
- CFO transition: Theodora Mistras, currently CFO of Viatris (since March 2024), becomes Edwards' CFO effective May 29, 2026, succeeding Scott Ullem, who has served as CFO since 2014.
- Planned handover: Ullem's departure was previously announced in October; he will continue as a strategic advisor, supporting an orderly transition.
- Base compensation: $925,000 annual salary with a target annual EIP bonus of at least 100% of base salary.
- Sign-on package: $2,013,000 sign-on bonus, with pro-rata repayment required if she resigns voluntarily or is terminated for misconduct within 24 months.
- Equity awards: $8,000,000 initial RSU grant vesting over three years (43.75% / 50% / 6.25%), plus a $4,500,000 grant-date value fiscal 2026 annual equity award.
- Severance protections: Change-in-control agreement provided; non-CIC severance is at least 1x base salary plus 1x target bonus, pro-rated bonus, and $50,000 outplacement, with initial RSUs fully vesting on qualifying terminations.
- No financial guidance or results disclosed in the filing; the press release is furnished under Item 7.01 and not deemed filed.
03—Questions
Frequently Asked Questions
Why is Edwards Lifesciences changing its CFO?
The change is a planned transition. Scott Ullem, CFO since 2014, announced his transition in October 2025 and will remain with the company as a strategic advisor in the months ahead. The filing does not indicate any disagreement or performance-related reason.
Who is Theodora Mistras and what is her background?
Mistras (age 44) has been CFO of Viatris since March 2024, overseeing its global finance organization, including financial planning, reporting, and operational finance. Before that, she was a managing director in healthcare investment banking at Citigroup (2019 to 2023) and spent over 15 years in healthcare investment banking at Goldman Sachs.
When does the new CFO take over, and does the appointment involve a fixed-term contract?
She becomes Corporate Vice President and CFO effective May 29, 2026. Her Offer Letter has no specified term and creates an at-will employment relationship, so either party can end the relationship at any time.
What are the main financial terms of her compensation package?
The package includes a $925,000 base salary, a target annual bonus of at least 100% of base, a $2,013,000 sign-on bonus (subject to a 24-month clawback on voluntary resignation or misconduct termination), an $8,000,000 initial RSU grant vesting over three years, and a $4,500,000 fiscal 2026 annual equity award. The company also covers up to $15,000 in legal fees and relocation from New York to the Orange County, California area.
Could this appointment affect Edwards' financial outlook?
The 8-K does not disclose any change to guidance, financial results, or strategy. The filing describes the appointment as a continuity-focused transition, and the press release emphasizes execution of the company's strategy and continued investment in innovation. Investors should look to management's upcoming earnings commentary for any changes in financial direction.
04—Continue